Triumeq is a drug that is used to treat patients with the human immunodeficiency virus (HIV) and is shown to be safe. It is thought that ancient viruses (retroviruses) have left their genetic material in our DNA during the human evolution. In some people, this old genetic material may become activated and is believed to be a cause of ALS. In a small trial, it has been shown that Triumeq could suppress this genetic reactivation and may slow disease progression in patients with ALS. Triumeq was shown to be safe and well tolerated in patients with ALS. With this clinical trial we aim to confirm the efficacy of Triumeq in patients with ALS.
The Lighthouse 2 trial is a randomized, double-blind, placebo-controlled study. This means that participants will be randomly allocated to receive a treatment with either Triumeq or a control medicine (placebo). During the study, both the patient and the research team do not know who is receiving the placebo treatment or Triumeq. This will help researchers to objectively assess the efficacy and side-effects of Triumeq.